血必净注射液联合替加环素治疗鲍曼不动杆菌肺部感染的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Xuebijing Injection combined with Tigefycline in the treatment of pulmonary infection of Acinetobacter Baumannii.Methods A total of 82 patients with pulmonary infection caused by Acinetobacter Baumannii treated in our hospital from January 2016 to April 2017 were selected as the subjects,and divided into control group and treatment group according to the PC random table method,with 41 cases in each group.The control group received Tegocycline,and the treatment group received Xuebijing Injection combined with Tigecycline.They were treated for 7 to 15 days.Peripheral blood was collected,and the clinical efficacy,C reactive protein (CRP),procalcitonin (PCT),immunoglobulin IgA,IgM and IgG were compared between the two groups.Results The total effective rate of the treatment group was lower than that of the control group,and the difference was statistically significant(P＜0.05).After treatment,the levels of CRP,PCT,IgA in the treatment group were lower than those in the control group,the differences were statistically significant(P＜0.05).The levels of IgM,IgG in the treatment group were higher than those in the control group,and the differences were statistically significant(P＜0.05).Conclusion Xuebijing injection combined with tigecycline has a remarkable effect on pulmonary infection caused by Acinetobacter Baumannii,which can reduce levels of CRP and PCT.

Key words： Xuebijing Injection Tigecycline Acinetobacter baumannii Pulmonary infection Inflammatory factors Immune function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HE Wei
	MU Xiao-dong
	JIA Hui

Cite this article:

HE Wei,MU Xiao-dong,JIA Hui. Study on the clinical effect of Xuebijing Injection combined with Tigefycline in the treatment of pulmonary infection of Acinetobacter Baumannii[J]. 中国当代医药, 2019, 26(5): 31-33-37.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I5/31

[1]	Knight D，Dimitrova DD，Rudin SD，et al.Mutations decreasing intrinsic β-lactam resistance are linked to cell division in the nosocomial pathogen acinetobacter baumannii[J].Antimicrob Agents Chemother，2016，60（6）：3751.
[2]	刘青松.鲍曼不动杆菌的耐药机制研究进展[J].中国微生态学杂志，2015，27（1）：108-111.
[3]	白艳，马新，郑晶晶，等.血必净治疗广泛耐药鲍曼不动杆菌所致重症肺炎疗效探讨[J].河北医学，2017，23（4）：662-665.
[4]	蒋福初，林书生，阙军.ICU重症患者医院获得性肺炎鲍曼不动杆菌感染高危因素及耐药性分析[J].江苏医药，2016，42（11）：1292-1293.
[5]	孙洪，张秀琴，周冬梅.综合ICU多重耐药鲍曼不动杆菌医院感染暴发调查与防控措施[J].中国消毒学杂志，2014，31（3）：268-270.
[6]	夏品江，张舸.替加环素在多重或泛耐药鲍曼不动杆菌引起的重症医院获得性肺炎治疗中的运用价值[J].中华全科医学，2017，15（3）：404-406.
[7]	董天皞，张桂萍，董凯.血必净注射液治疗脓毒症作用机制的研究进展[J].中国中西医结合急救杂志，2016，23（5）：554-557.
[8]	何先弟，颜培娥，邹琪，等.血必净对鲍曼不动杆菌脓毒症大鼠肝脏组织翻译控制肿瘤蛋白表达的影响[J].中华危重病急救医学，2013，25（9）：537-541.
[9]	周灿富，杨保生，蔡海林，等.降钙素原对高龄社区获得性肺炎患者病情的预测价值研究[J].安徽医药，2014，（6）：1091-1093.
[10]	姜友珍，李爽，侯德风，等.降钙素原、C反应蛋白、白细胞计数联合检测在ICU医院获得性细菌性肺炎鉴别诊断中的价值[J].检验医学，2016，31（6）：453-457.
[11]	吴会玲，宋希，申玉英.血必净注射液联合人免疫球蛋白治疗重症病毒性肺炎的临床研究[J].现代药物与临床，2016，31（11）：1725-1728.
[12]	艾学才.血清PCT、CRP联合检测对老年肺炎病情诊疗及预后的价值探究[J].临床肺科杂志，2016，21（6）：1045-1048.
[13]	张鹏，李淑芸，杜云波，等.替加环素治疗耐碳青霉烯鲍曼不动杆菌感染的临床疗效[J].中国感染控制杂志，2016，15（6）：380-383.
[14]	夏琪.血清炎性细胞因子、PCT和CRP在支原体与细菌性肺炎中的水平变化及临床意义[J].中国微生态学杂志，2015，27（8）：935-937.
[15]	肖洋，赵鸣雁.降钙素原与肺部感染多重耐药鲍曼不动杆菌患者病情程度的相关性[J].中国老年学杂志，2017，37（22）：5637-5639.